JAK

The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.

Cat. No.	Product name	CAS No.	Purity
T3066	S-Ruxolitinib	1160597-27-2	99.75%
T3066	Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivi...
T22319	DTP3	1809784-29-9	99.57%
T22319	DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.
T2460	JAK 3 inhibitor IV	58753-54-1	98%
T2460	JAK 3 inhibitor IV is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutam...
T2653	SB1317	1204918-72-8	100%
T2653	SB1317 is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
T11710L	JAK-IN-5 hydrochloride	2751323-21-2
T11710L	JAK-IN-5 hydrochloride is a JAK inhibitor [1].
T11709	JAK3 covalent inhibitor-1	2300106-50-5	98%
T11709	JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs.
T11713	JBJ-02-112-05	2748162-29-8	98%
T11713	JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].
T16995	TAS05567	1429038-15-2	98%
T16995	TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
T9814	JAK3/BTK-IN-1	2674036-91-8	98%
T9814	JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important target...
T15606	JAK1-IN-4	2091134-35-7	98%
T15606	JAK1-IN-4 is a selective JAK1 inhibitor (IC50s: 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively). JAK1-IN-4 inhibits STAT3 phosphorylation in NC...
TN2511	Britannilactone diacetate	1286694-67-4	98%
TN2511	1,6-O,O-Diacetylbritannilactone(OODBL) has anti-inflammatory activity, it has a potential therapeutic efficacy on inflammatory diseases especially allergic airwa...
T11721L	JDTic dihydrochloride	785835-79-2	98%
T11721L	JDTic is a potent antagonist of kappa-opioid receptors (KOR), blocking the κ-agonist U50, 488-induced antinociception.
TN4774	Physalin A	23027-91-0	98%
TN4774	Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling, it inhibits androgen-independent prostate canc...
T11708	JAK2-IN-4	1438284-00-4	98%
T11708	JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.
T5049	NVP-BSK805	1092499-93-8	98%
T5049	NVP-BSK805 is an ATP-competitive JAK2 inhibitor.
TMA1743	Ergosterol peroxide	2061-64-5	98%
TMA1743	Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Fox...
T15037	Momelotinib Mesylate	1056636-07-7	98%
T15037	Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.
T10009	JAK3-IN-7	1263774-57-7	98%
T10009	JAK3-IN-7 is an effective and selective JAK3 inhibitor (IC50 <0.01 μM) extracted from patent WO2011013785A1.
T4S1499	Ginsenoside Rk1	494753-69-4	98%
T4S1499	Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures. Ginsenoside Rk1 has an anti-inflammatory effect, suppresses the acti...
TQ0061	CHZ868	1895895-38-1	98%
TQ0061	CHZ868 is a type II JAK2 inhibitor (IC50: 0.17 μM in EPOR JAK2 WT Ba/F3 cell).